First month on GLP-1 drugs: what the evidence actually shows

What's this video probably claiming?

A chiropractor using the handle @dr_jonesdc is almost certainly walking viewers through a month-one timeline for tirzepatide or semaglutide, the two GLP-1 (and in tirzepatide's case, GIP) receptor agonists dominating weight-loss conversations right now. Expect claims about when nausea peaks, when appetite suppression kicks in, how much weight you might lose in the first four weeks, and possibly some reassurance that side effects are temporary. Creators in this space often frame the first month as a rough but necessary initiation period, and they typically cite 5 to 10 percent body weight loss over a longer arc as the payoff. There may also be discussion of dose titration, since both drugs start low and escalate over weeks to months. The hashtags signal this is squarely promotional territory, even if the framing is educational.

What does the science actually show?

The clinical trial data on first-month outcomes is actually fairly consistent. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on tirzepatide lost a mean of roughly 2 to 3 percent of body weight by week four at the starting dose, with the dramatic numbers accumulating over 72 weeks. The STEP 1 trial for semaglutide (Wilding et al., 2021, NEJM) showed similar early modest losses before dose escalation. Gastrointestinal side effects, primarily nausea, vomiting, and diarrhea, peak during the titration phase, with approximately 44 percent of semaglutide users reporting nausea in STEP 1. Appetite suppression is real and measurable from week one, but the mechanism involves slowing gastric emptying as much as central satiety signaling, which explains why GI distress and appetite reduction arrive together. Month one is genuinely the hardest stretch for tolerability, and that part checks out.

Where does the social media noise diverge from clinical reality?

The gap between TikTok timelines and clinical reality shows up in a few specific places. First, creators routinely overstate month-one weight loss. Losing 10 or even 15 pounds in the first month gets shared constantly, but those numbers usually reflect water weight and glycogen depletion, not fat mass, and they are not representative of average trial outcomes. Second, the framing of side effects as universally brief and manageable ignores that roughly 4 to 6 percent of participants in major trials discontinued due to GI adverse events. Third, a chiropractor discussing GLP-1 medications is practicing outside their licensed scope in most states. Chiropractic licensure does not include prescribing authority or pharmacological counseling. That does not make every claim wrong, but it should make you skeptical about nuance, dosing context, and the absence of contraindication discussion. The lack of any mention of pancreatitis risk, thyroid C-cell concerns, or gallbladder disease in these videos is a pattern worth noting.

What should you actually know?

If you are starting a GLP-1 medication, here is what the trials actually support for month one. Expect modest early weight loss, typically 1 to 4 percent of body weight, not the dramatic drops you see in before-and-after posts. Nausea is common and tends to be worst in the first two to four weeks at each new dose level. Eating smaller meals, avoiding high-fat foods, and staying hydrated genuinely helps based on patient-reported data. Appetite suppression is real from early on, but do not interpret complete loss of hunger as a sign to skip meals entirely. Protein intake and resistance training matter for preserving lean mass during weight loss, something rarely mentioned in these videos. Finally, month one outcomes are a poor predictor of long-term results. The SURMOUNT-1 and STEP trials both show that weight loss accelerates and then plateaus over 12 to 18 months, so early slow progress is not a failure signal.